Permeability of the Blood-Brain Barrier Predicts No Evidence of Disease Activity at Two Years After Natalizumab or Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis
Annals of Neurology - United States
doi 10.1002/ana.25219
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 1, 2018
Authors
Publisher
Wiley